Document is current
Any future updates will be listed below
-
Authors
Hamid, Omid https://orcid.org/0000-0002-8238-4655
Chiappori, Alberto A
Thompson, John A https://orcid.org/0000-0002-7877-1580
Doi, Toshihiko
Hu-Lieskovan, Siwen
Eskens, Ferry A L M
Ros, Willeke
Diab, Adi https://orcid.org/0000-0002-0153-0244
Spano, Jean-Philippe https://orcid.org/0000-0002-3921-2479
Rizvi, Naiyer A https://orcid.org/0000-0002-1134-7494
Wasser, Jeffrey S https://orcid.org/0000-0001-5917-2796
Angevin, Eric https://orcid.org/0000-0001-6249-7209
Ott, Patrick A https://orcid.org/0000-0002-4253-943X
Forgie, Alison
Yang, Wenjing
Guo, Cen https://orcid.org/0000-0001-6850-1045
Chou, Jeffrey https://orcid.org/0000-0001-9232-0092
El-Khoueiry, Anthony B https://orcid.org/0000-0002-9053-3841
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02315066 at ClinicalTrials.govnct02554812 at ClinicalTrials.govDocuments that mention this clinical trial
P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort
https://doi.org/10.1136/lba2019.14
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2022-005471
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
https://doi.org/10.1136/jitc-2021-002591
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells
https://doi.org/10.1136/jitc-2020-000816
nct03217747 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2022-005471
nct03971409 at ClinicalTrials.govDocuments that mention this clinical trial
191 Tumor microenvironment changes after treatment with avelumab combinations in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2025-sitc2025.0191
8 Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist
https://doi.org/10.1136/jitc-2020-sitc2020.0008
584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies
https://doi.org/10.1136/jitc-2023-sitc2023.0584
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2022-005471
nct02554812 at ClinicalTrials.govDocuments that mention this clinical trial
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2022-005471
Documents that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2022-005471
-
Funding
Funding for this research was provided by:
Pfizer (N/A)
- License Information
